Incyte faces delay on FDA's Jakafi decision for cGVHD; Bayer's Parkinson's cell therapy enters the clinic
Just 10 months after Incyte posted an upbeat assessment for Jakafi in a Phase III for chronic graft-versus-host disease, the FDA has opted to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
